Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials.
暂无分享,去创建一个
[1] R. Frumento,et al. Stroke after cardiac surgery: a retrospective analysis of the effect of aprotinin dosing regimens. , 2003, The Annals of thoracic surgery.
[2] D. Mangano. Aspirin and mortality from coronary bypass surgery. , 2002, The New England journal of medicine.
[3] P. Raven,et al. Intraoperative treatment strategy to reduce the incidence of postcardiopulmonary bypass atrial fibrillation , 2002, Perfusion.
[4] WM Weightmen,et al. Pharmacological strategies for blood loss , 2001, The Lancet.
[5] D. Haskard,et al. Leukocyte integrin expression in patients undergoing cardiopulmonary bypass. , 2000, The Annals of thoracic surgery.
[6] B. Garayar,et al. Comparison of two doses of aprotinin in patients receiving aspirin before coronary bypass surgery , 2000, Perfusion.
[7] M. Prins,et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints , 1999, The Lancet.
[8] B. Chaitman,et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. , 1998, The Journal of thoracic and cardiovascular surgery.
[9] D. Royston. Aprotinin versus lysine analogues: the debate continues. , 1998, The Annals of thoracic surgery.
[10] N. Hayashida,et al. Effects of minimal-dose aprotinin on coronary artery bypass grafting. , 1997, Journal of Thoracic and Cardiovascular Surgery.
[11] Simon M. Shane,et al. Meta-analysis, decision analysis and cost-effectiveness analysis: methods for quantitative synthesis in medicine , 1997 .
[12] J. Copeland,et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. , 1996, The Annals of thoracic surgery.
[13] L. Muhlbaier,et al. Aprotinin: safe and effective only with the full-dose regimen. , 1996, The Annals of thoracic surgery.
[14] A R Jadad,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.
[15] L. Hedges,et al. The Handbook of Research Synthesis , 1995 .
[16] R. E. Clark,et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. , 1995, Circulation.
[17] M. Jochum,et al. Influence of High-dose Aprotinin on Anticoagulation, Heparin Requirement, and Celite- and Kaolin-Activated Clotting Time in Heparin-pretreated Patients Undergoing Open-Heart Surgery: A Double-blind, Placebo-controlled Study , 1995, Anesthesiology.
[18] R. Hanka. The Handbook of Research Synthesis , 1994 .
[19] Diana B. Petitti,et al. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine , 1994 .
[20] G. Guiraudon,et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. , 1994, The Journal of thoracic and cardiovascular surgery.
[21] C. Tatooles,et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. , 1994, The Journal of thoracic and cardiovascular surgery.
[22] F. Loop,et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. , 1992, The Annals of thoracic surgery.
[23] E. Simonson,et al. The Electrocardiogram in Population Studies: A Classification System , 1960, Circulation.
[24] J. Fontcuberta,et al. The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss. , 2000, Haematologica.